Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$24k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
50.2% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
New
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
3.4% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
1
users have commented on this narrative
15
users have followed this narrative
7 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
1.4% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
52.2% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
CareDx
AN
AnalystHighTarget
Consensus Narrative from 5 Analysts
AlloSure And AlloMap Will Boost Molecular Transplant Care Despite Hurdles
Key Takeaways Breakthroughs in AI-driven diagnostics, digital health expansion, and strong clinical validation position CareDx for outsized revenue growth and margin acceleration beyond current forecasts. Advanced digitization and integration with major healthcare platforms streamline operations, enhancing net margins, cash flow, and creating sticky, high-margin recurring revenue streams.
View narrative
US$28.00
FV
57.7% undervalued
intrinsic discount
16.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Maravai LifeSciences Holdings
AN
AnalystHighTarget
Consensus Narrative from 8 Analysts
mRNA And Cell Therapy Demand Will Transform Global Markets
Key Takeaways Aggressive cost reductions and organizational streamlining are poised to significantly boost operating leverage, driving margin expansion and rapid earnings recovery. Maravai's leadership in innovation, global expansion, and specialized biotech solutions positions it for sustained top-line outperformance and resilient, long-term revenue growth.
View narrative
US$5.00
FV
48.6% undervalued
intrinsic discount
4.18%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Alpha and Omega Semiconductor
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Electrification, Renewables And IoT Will Drive Enduring Market Leadership
Key Takeaways Rapid AI, graphics, and e-mobility adoption positions the company for significant growth, margin expansion, and deeper integration across hyperscale, consumer, and automotive markets. Enhanced financial strength enables aggressive investment in innovation and manufacturing, boosting competitiveness in high-value segments like renewables and industrial automation.
View narrative
US$35.00
FV
24.5% undervalued
intrinsic discount
6.72%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Arvinas
AN
AnalystHighTarget
Consensus Narrative from 18 Analysts
Precision Medicine Trends Will Expand PROTAC Applications Despite Risks
Key Takeaways Regaining global rights and leveraging AI-driven PROTAC design could unlock significant revenue, pipeline productivity, and long-term earnings power through licensing or strategic transactions. Pipeline breakthroughs and industry shifts toward targeted protein degradation position Arvinas for rapid market expansion, revenue diversification, and enhanced valuation.
View narrative
US$63.50
FV
88.7% undervalued
intrinsic discount
-12.13%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
TechTarget
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Digital Transformation And First-Party Data Will Ignite Secular Demand
Key Takeaways Enhanced AI integration and brand consolidation are driving higher market share, client retention, and recurring revenue while reducing exposure to economic cycles. Operational efficiencies and ecosystem integration are strengthening margins, cash flow, and the company's essential role in B2B technology markets.
View narrative
US$15.00
FV
58.5% undervalued
intrinsic discount
18.14%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Delek US Holdings
AN
AnalystHighTarget
Consensus Narrative from 12 Analysts
Secular Energy Demand And Renewables Will Energize US Refining
Key Takeaways Strong operational execution and efficiency initiatives position Delek for sustained margin expansion and earnings growth, potentially exceeding current expectations. Strategic investments in renewables and logistics diversify revenue streams, de-risk the business, and enhance valuation and margin resilience.
View narrative
US$30.00
FV
23.7% undervalued
intrinsic discount
0.68%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Ocular Therapeutix
AN
AnalystHighTarget
Consensus Narrative from 11 Analysts
Aging Global Trends And Novel Delivery Will Expand Markets
Key Takeaways AXPAXLI's unique clinical advantages and potential label claims support premium pricing, durable market share, and strong long-term margin expansion insulated from price competition. Platform innovation and demographic-driven demand growth open multiple recurring revenue streams, reduce business risk, and increase chances of major partnerships or acquisition.
View narrative
US$22.00
FV
44.0% undervalued
intrinsic discount
62.81%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Altice USA
AN
AnalystHighTarget
Consensus Narrative from 15 Analysts
Accelerated Fiber Expansion Will Spark Premium Broadband Demand
Key Takeaways Accelerated fiber and AI-driven operational gains, along with innovative financing, are positioning the company for significantly stronger revenue and margin performance. Expansion into underpenetrated markets and rapid adoption of premium products are creating new high-margin revenue streams and enhancing long-term growth potential.
View narrative
US$5.37
FV
56.6% undervalued
intrinsic discount
-1.82%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
agilon health
AN
AnalystHighTarget
Consensus Narrative from 14 Analysts
Aging Population And Value-Based Care Will Expand Opportunities
Key Takeaways Strategic focus on higher-value contracts, data analytics, and top-performing partners sets the stage for improved margins and predictable, higher-quality revenue. agilon's value-based care platform, enabled by AI and physician partnerships, is well-positioned for durable growth and market share gains as the industry shifts.
View narrative
US$4.14
FV
70.3% undervalued
intrinsic discount
13.84%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Value any company in seconds
Popular companies